Ensayos clínicos

Exclusion criteria for participants

• Pregnant, trying to become pregnant or lactating
• Diabetes
• Alcohol or drug abuse within the last year by history
• Active Crohn's disease as evaluated by standard procedures employed by the investigator.
• History of radiation enteritis, scleroderma, celiac disease, tropical sprue, diabetes, chronic pseudo-obstruction or malignancies.
• Previous use of Teduglutide or potential allergies to Teduglutide or its constituents
• Any hospitalization within 1 month before screening
• Use of Infliximab, growth hormone or growth factors such as native GLP-2 or other biological therapy within the last 12 weeks.
• Use of Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, Octreotide, intravenous glutamine or any investigational drug within last 30 days.
• Diuretics and oral rehydration solutions will be required to be stable for ≥4 weeks prior to baseline evaluations and remain stable during the study.
• Change in dose of antimotility or secretory agents from 2 days prior to, and throughout the two phases and washout periods of the study
• Use of tobacco products within the prior 1 month (since nicotine can affect permeability)
• Use of NSAIDS or aspirin within the past week
• Use of oral corticosteroids within the previous 6 weeks
• Ingestion of artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), lactulose or mannitol 2 days each of the study measurement days, e.g. foods to be avoided are sugarless gums or mints and diet soda.
• History of pancreatitis
• Primary renal impairment (estimated GFR [eGFR] <30 ml/min).